Financial Contrast: Juniper Pharmaceuticals (JNP) versus Patheon NV (PTHN)
Juniper Pharmaceuticals (NASDAQ: JNP) and Patheon NV (NASDAQ:PTHN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitabiliy and dividends.
This table compares Juniper Pharmaceuticals and Patheon NV’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Juniper Pharmaceuticals and Patheon NV, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Juniper Pharmaceuticals presently has a consensus target price of $9.38, indicating a potential upside of 85.64%. Patheon NV has a consensus target price of $32.45, indicating a potential downside of 6.94%. Given Juniper Pharmaceuticals’ higher probable upside, analysts plainly believe Juniper Pharmaceuticals is more favorable than Patheon NV.
Valuation and Earnings
This table compares Juniper Pharmaceuticals and Patheon NV’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Juniper Pharmaceuticals||$55.34 million||0.99||$7.46 million||$0.61||8.28|
|Patheon NV||$1.93 billion||2.62||$352.50 million||N/A||N/A|
Patheon NV has higher revenue and earnings than Juniper Pharmaceuticals.
Insider & Institutional Ownership
34.3% of Juniper Pharmaceuticals shares are owned by institutional investors. 11.6% of Juniper Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that addresses unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Patheon NV Company Profile
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.